Clinical trials: Colo -Rectal Surgeries
Rectal Cancer, Colo-rectal Cancer
Pre-therapeutic MRI Assessment of Early-Stage Rectal Cancer and Significant Rectal Polyps to Avoid Major Resectional Surgery
When a patient is diagnosed with a rectal (bowel) polyp or cancer, radiology doctors read MRI scans to describe how deeply the cancer invades into the bowel wall (this is the 'stage' of the cancer).
- Trial name
- PRESERVE (NCT04103372)
- Testing
- MRI scan, Radiologist training
- Where
- 23 sites in United Kingdom
- Volunteers
- 200 people
- Sponsor
- Imperial College London
Colo-rectal Cancer, Anastomosis, Leaking
The Factors Influencing the Success of Redo Surgery and Anal Function for Anastomosis Failure or Local Tumor Recurrence
To analyze the influencing factors of the success of redo surgery due to anastomotic fistula or anastomotic recurrence after rectal cancer surgery and to evaluate the anal function of patients
- Trial name
- NCT07440888
- Testing
- redo surgery
- Volunteers
- 143 people
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Colon Rectal Cancer, Surgical Site Infection
Surveillance and Implementation of a Bundle of Care to Reduce Surgical Site Infection in Colorectal Surgery (CCR-VINCat)
The Nosocomial Infection Surveillance Program in Catalonia (VINCat) monitors surgical site infection (SSI) in elective colorectal surgery since 2007 in 55 public and private acute care hospitals.
- Trial name
- CCR-VINCat (NCT04496635)
- Testing
- Implementation of a bundle of care
- Where
- Spain
- Volunteers
- 60,000 people
- Sponsor
- Hospital de Granollers
Colon Rectal Cancer Duke Stage Stageval
A Trial of Pre-Operative Chemoradiotherapy Using Capecitabine, Radiation & Cetuximab, in Rectal Cancer
A Pilot Trial of Pre-Operative Chemoradiotherapy Using Capecitabine (Xelodaâ), External Beam Radiation and Cetuximab (Erbitux®) Followed by Definitive Surgery in Patients With Localized (Non-Metastatic) Rectal Cancer
- Trial name
- NCT01310985
- Testing
- Capecitabine (Xelodaâ), XRT & Cetuximab (Erbitux®)
- Where
- Saudi Arabia
- Volunteers
- 15 people
- Sponsor
- King Faisal Specialist Hospital & Research Center
Colo-rectal Cancer
Outcomes of Elective Colorectal Cancer Surgery During COVID 19 Pandemic: Implications for Cancer Care Policy
Due to COVID 19 (Corona virus disease)pandemic, majority of surgeries, including surgery for cancer patients got delayed across the globe. Surgeries were limited to emergency set up only.
- Trial name
- NCT04588909
- Testing
- Colorectal resections
- Where
- India
- Volunteers
- 100 people
- Sponsor
- Sheri Kashmir Institute of Medical Sciences
Anorectal Malformation, Hirschprung's Disease
Long-Term Health Outcomes in Children Born With Hirschsprung's Disease and Anorectal Malformations at the Colorectal Centre of Excellence in Quebec
The COCOE Registry is a long-term research registry based at the Montreal Children's Hospital Colorectal Centre of Excellence (COCOE) in Montreal, Quebec.
- Conditions
- Anorectal Malformation, Hirschprung's Disease, Colo-rectal Surgery, Fecal Incontinence
- Trial name
- NCT07603232
- Testing
- No intervention (observational study)
- Where
- Canada
- Volunteers
- 999 people
- Sponsor
- McGill University Health Centre/Research Institute of the McGill University Health Centre
Colo-rectal Cancer, Colon Cancer
Delayed Colorectal Cancer Care During Coronavirus Disease (COVID-19) Pandemic (DECOR-19)
To understand and analyse the global impact of COVID-19 on outpatient services, inpatient care, elective surgery, and perioperative colorectal cancer care, a DElayed COloRectal cancer surgery (DECOR-19) survey was conducted in…
- Conditions
- Colo-rectal Cancer, Colon Cancer, Rectal Cancer, Oncology
- Trial name
- DECOR-19 (NCT04488549)
- Testing
- Survey
- Where
- Italy
- Volunteers
- 1,051 people
- Sponsor
- Treviso Regional Hospital
Colo-rectal Cancer
EMVI as a Determinant of Metastasis in Colorectal Cancer
Bowel cancer is the fourth most commonly occurring cancer and the second highest cause of cancer deaths in the UK. Despite advances in treatment, over 40% of patients will die within 5 years.
- Trial name
- EVIDENCE (NCT06646341)
- Where
- United Kingdom
- Volunteers
- 100 people
- Sponsor
- Imperial College London